Search Medical Condition
Please enter condition
Please choose location

Stafa, Switzerland Clinical Trials

A listing of Stafa, Switzerland clinical trials actively recruiting patients volunteers.

RESULTS

Found (15) clinical trials

Quest Sound Recover (SR2) vs. Venture SR2

Goal of this study is to determine the benefit of an improved feature on a new hearing aid platform. To investigate the improvements of this feature is compared on a new and older hearing aid platform. The obtained results will be used for future improvement for this feature. This feature ...

Phase N/A

0.72 miles

Learn More »

The Phonak EduLink-System in Students With Specific Performance Deficits in Speech-in-Noise Intelligibility

In the management and remediation of students with specific performance deficits in speech-in-noise intelligibility, most often, a "triad" approach for treatment is used, which includes direct therapy, compensatory strategies, and environmental modifications. The purpose of the study is to determine whether a new hearing aid, the Phonak EduLink-FM System, can ...

Phase N/A

0.72 miles

Learn More »

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

Due to a rising number of elderly patients, fit for chemotherapy, investigating a well-tolerated and effective first line treatment is warranted. In this specific population often there are contra-indications for the use of standard first line drugs like anthracyclines and taxanes due to comorbidities (e.g. cardiac impairment or Peripheral neuropathy). ...

Phase

2.35 miles

Learn More »

Treatment of Complaints Following Sports Injuries With Traditional Chinese Medicine

In Switzerland, still very little is known about the treatment with TCM (acupuncture, Chinese medicinal therapy, Tuina massage, nutrition, qigong) under everyday conditions. The importance of non-medical therapists in the healthcare system is rarely investigated. It is likely that patients with chronic injuries use several therapies (including conventional medicine) in ...

Phase N/A

6.0 miles

Learn More »

BAsel Syncope EvaLuation (BASEL IX) Study

Background: Management of patients with syncope is a serious problem concerning 1-2% of emergency department (ED) visits. In 6-20% of these, syncope will be due to a cardiac origin. The rapid and accurate identification of these patients is an important unmet clinical need. Aim: The aim of the study is ...

Phase N/A

6.49 miles

Learn More »

Anti-Angiotensin-Receptor 1 (ATR1)- Anti-Endothelin-Receptor A (ETRA)-Antibodies and T Cells in Cardiomyopathy

AIM OF THE STUDY 1.1. Background Progressive interstitial fibrosis parallels pathological remodeling in the failing heart. This is particularly the case in patients with post-inflammatory dilated cardiomyopathy, but is also observed in ischemic and hypertensive heart disease. Both, Angiotensin II (AngII) and Endothelin-1 (ET1) induce the formation of the profibrotic ...

Phase N/A

6.51 miles

Learn More »

Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma

Follicular lymphomas FL has been traditionally approached either by an initial watch and wait policy in the asymptomatic patient, or with single agent treatments with the purpose of maintaining a good quality of life for a prolonged time. During the last decades, treatment strategies have changed due to the continuous ...

Phase

7.53 miles

Learn More »

Quality of Life Measurement in Treatment Na ve Patients With HCV Genotype 1 Suffering From Fatigue and Receiving Ombitasvir Paritaprevir and Ritonavir and Dasabuvir (Viekirax /Exviera )

This is an observational, prospective, open-label, single-arm, multicenter, real-life study designed to observe the impact of paritaprevir/ritonavir/ombitasvir with dasabuvir regimen (Viekirax®/Exviera®, 3D regimen) on total daytime physical activity and fatigue in participants with Hepatitis C Virus (HCV) genotype 1 (GT1).

Phase N/A

8.38 miles

Learn More »

Sequential Combo Immuno and Target Therapy (SECOMBIT) Study

The combination BRAF (B-raf murine sarcoma viral oncogene homolog B1) inhibitor plus mitogen-activated protein kinase (MEK) inhibitor seems to be more effective in the V600 BRAF mutated advanced melanoma patients compared to treatment with the BRAF inhibitors alone. In fact, a phase I-II study showed a better overall response rate ...

Phase

8.65 miles

Learn More »

ArmeoSenso - Reward

Rewards not only increase motivation to train, but have also been shown to influence motor skill learning via activation of dopaminergic brain structures. In goal oriented tasks, receiving information about goal achievement has a rewarding value, which is further increased if performance has monetary consequences. Computer games often strengthen this ...

Phase N/A

8.86 miles

Learn More »